Intralesional measles, mumps, and rubella vaccine after failure of intralesional Candida antigen for the treatment of recalcitrant pediatric warts

• Published in: Pediatric dermatology 2023-11, Vol.40 (6), p.1057-1059
• Main Authors: Ulschmid, Caden M., Patel, Jay, Pan, Amy Y., Liegl, Melodee, Holland, Kristen E.
• Format: Article
• Language: English
• Subjects: Candida; Immunotherapy; Measles; Mumps; Patients; Pediatrics; retrospective studies; Rubella; Skin diseases; Vaccines; Warts
• ISSN: 0736-8046; 1525-1470
• DOI: 10.1111/pde.15415

Numerous studies have investigated the efficacy of intralesional immunotherapy for warts, but there are a lack of studies investigating the efficacy of alternative intralesional immunotherapies following failure of initial intralesional immunotherapy. In this retrospective study, we aimed to investigate the efficacy of intralesional measles, mumps, and rubella vaccine for the treatment of pediatric warts following failure of intralesional therapy with Candida antigen. Following intralesional measles, mumps, and rubella vaccine administration, 8/51 (15.5%) patients had complete resolution of their warts, 6/51 (12%) had near complete resolution, 19/51 (37%) had partial improvement, 12/51 (23.5%) had no change, and 6/51 (12%) had worsening. Although limited by retrospective nature and low sample size, our results demonstrate that intralesional immunotherapy with measles, mumps, and rubella vaccine provides an alternative therapeutic option for the treatment of recalcitrant pediatric warts in patients who fail to respond to intralesional Candida antigen.